CV Sciences, UCSD Publish Nicotine Dependence Study

A California cannabidiol (CBD) company has published the results of a preclinical study focusing on using CBD to reduce nicotine withdrawal symptoms in smokeless tobacco users.

San Diego-based CV Sciences today announced the publication of the study, which the company performed in collaboration with the University of California San Diego.

CBD Helps

CV Sciences says that CBD has demonstrated the ability to reduce alcohol and cocaine cravings and modulate nicotinic receptor function.

According to the results of the new study, CBD prevented nicotine-dependent rats from experiencing withdrawal symptoms, like increased pain sensitivity and weight gain, during short- and long-term nicotine restriction.

“We are very pleased with the outcome of the research completed in collaboration with UC San Diego, which further validates our years of investment and hard work,” says CV Sciences CEO Joseph Dowling. “This study marked a key milestone in CV Sciences’ smokeless tobacco addiction treatment R&D efforts, and further extends our potential product development opportunities to commercialize the world’s first and only FDA-approved treatment for smokeless tobacco addiction to address a huge unmet medical need and global health issue.”

CV Sciences says the study results advance the development and commercialization of a CBD-based product to treat nicotine addiction.

According to the company, it is working on a solution to treat people’s nicotine cravings and the desire to have chew, snuff, or a tobacco pouch in their mouth.

CV Sciences says the global smokeless tobacco addiction treatment market, currently valued at more than $2 billion.

The company says the market provides a long-term growth channel in addition to its consumer product segment.

Making it Official

In May 2020, CV Sciences obtained a formal Notice of Issuance from the U.S. Patent and Trademark Office.

The Notice of Issuance was regarding CV Sciences’ patent application for a CBD and nicotine formulation to treat smokeless tobacco addictions.

CV Sciences says the patent covers smokeless tobacco addiction treatment through pharmaceutical CBD and nicotine formulation administration.

According to CV Sciences, it has filed corresponding patent applications to obtain similar patent protections in other key global markets.